Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,428,912.10. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $1.60 during midday trading on Thursday, hitting $84.18. The stock had a trading volume of 6,522,001 shares, compared to its average volume of 4,524,115. The firm’s fifty day moving average is $88.79 and its two-hundred day moving average is $86.15. The company has a market capitalization of $48.47 billion, a PE ratio of 48.38, a P/E/G ratio of 2.27 and a beta of 0.87. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Edwards Lifesciences in the second quarter worth $5,318,092,000. Varma Mutual Pension Insurance Co bought a new position in Edwards Lifesciences during the second quarter valued at $11,168,000. Conway Capital Management Inc. bought a new position in Edwards Lifesciences during the second quarter valued at $954,000. Commerce Bank purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $3,121,000. Finally, Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $605,397,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on EW. UBS Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Thursday. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, BTIG Research reissued a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.